biostudies-literatureBooyse RPNIH/NHGRINHGRI NIH HHSUniversity of the WitwatersrandSydney Brenner Charitable Trust845-857https://www.ebi.ac.uk/biostudies/studies/S-EPMC10694788biostudies-literatureUnknown24(16)<b>Background:</b> <i>CYP2C19</i> is important in the metabolism of clopidogrel and several antidepressants. This study aimed to characterize the distribution of <i>CYP2C19</i> star alleles (haplotypes) across diverse African populations compared with global populations. <b>Methods:</b> <i>CYP2C19</i> star alleles and diplotypes were called from high coverage genomes using the StellarPGx pipeline. <b>Results:</b> <i>CYP2C19*1</i> (51%), <i>*2</i> (17%) and <i>*17</i> (22%) were the most common star alleles across African populations in this study. It was observed that 3% of African participants had potentially novel <i>CYP2C19</i> haplotypes. <b>Conclusion:</b> This study supports the necessity for <i>CYP2C19</i> pharmacogenetic testing in African and global clinical settings, as well as tPharmacogenomicsCharacterization of <i>CYP2C19</i> pharmacogenetic variation in African populations and comparison with other global populations.PMC10694788UM1 HG008901U54 HG006938U54HG006938Twesigomwe DHazelhurst SBooyse RPfalseCharacterization of <i>CYP2C19</i> pharmacogenetic variation in African populations and comparison with other global populations.<b>Background:</b> <i>CYP2C19</i> is important in the metabolism of clopidogrel and several antidepressants. This study aimed to characterize the distribution of <i>CYP2C19</i> star alleles (haplotypes) across diverse African populations compared with global populations. <b>Methods:</b> <i>CYP2C19</i> star alleles and diplotypes were called from high coverage genomes using the StellarPGx pipeline. <b>Results:</b> <i>CYP2C19*1</i> (51%), <i>*2</i> (17%) and <i>*17</i> (22%) were the most common star alleles across African populations in this study. It was observed that 3% of African participants had potentially novel <i>CYP2C19</i> haplotypes. <b>Conclusion:</b> This study supports the necessity for <i>CYP2C19</i> pharmacogenetic testing in African and global clinical settings, as well as t2023-01-01T00:00:00Z2023 Nov2026-06-02T04:01:18.134Z2025-04-06T00:58:35.52ZS-EPMC106947883792932610.2217/pgs-2023-0166